Search Results:
CLINICAL TRIAL 18964
Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of the Activated B-cell Subtype
Disease Site: Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 19627
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission
Disease Site: Non-Hodgkin's Lymphoma, Lymphoma
View Trial DetailsCLINICAL TRIAL 19715
An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Mosunetuzumab (Btct4465a) In Combination With Polatuzumab Vedotin In Patients With B-Cell Non-Hodgkin Lymphoma
Disease Site: Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 19829
A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate the Safety and Clinical Activity of PBCAR0191 in Subjects with Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Disease Site: Non-Hodgkin's Lymphoma, Lymphoid Leukemia
View Trial DetailsCLINICAL TRIAL 19877
A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas
Disease Site: Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 19960
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501, an Anti-CD19 Allogeneic Car T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Patients with Relapsed/Refractory Large B-Cell and Follicular Lymphoma
Disease Site: Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 20069
A Phase 1, Multi-center, Open-label, Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of an Orally Available Small Molecule CC-99282 Alone and in Combination with Rituximab in Subjects with Relapsed and/or Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL) and Indolent Non-Hodgkin Lymphoma (R/R iNHL)
Disease Site: Lymphoid Leukemia, Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 20078
A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)
Disease Site: Lung, Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 20131
Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies
Disease Site: Hodgkin's Lymphoma, Leukemia, other, Lymphoid Leukemia, Myeloid and Monocytic Leukemia, Non-Hodgkin's Lymphoma, Other hematologic
View Trial DetailsCLINICAL TRIAL 20266
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects with Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
Disease Site: Hodgkin's Lymphoma, Other hematologic, Unknown Primary Site
View Trial DetailsCLINICAL TRIAL 20385
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin(Adcetris) Plus AVD in Patients (Age >/= 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Disease Site: Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 20571
Optimizing Cellular and Humoral Immunity to Pneumococcus by Vaccination with Pneumococcal 13-valent conjugate vaccine before and after CD19-targeted CAR T-cell Immunotherapy
Disease Site: Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 20578
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmocodynamics of ALLO-501A, an Anti-CD19 Allogeneic Car T Cell Therapy in Subjects with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
Disease Site: Non-Hodgkin's Lymphoma, Lymphoma
View Trial DetailsCLINICAL TRIAL 20600
A Phase I, Open-Label, Multicenter, Dose Escalation, Dose Expansion Study of PRT543 in Patients with Advanced Solid Tumors and Hematologic Malignancies
Disease Site: Lymphoma, Unknown Sites
View Trial DetailsCLINICAL TRIAL 20608
A Phase 1/2 Study Evaluating the Safety and Efficacy of IOV-2001 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Disease Site: Chronic Leukemia (CLL, CML), Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 90001
A Phase 2, Multicenter, Single-Arm Study of Retreatment with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classic Hodgkin lymphoma (cHL) or CD30-Expressing Peripheral T Cell Lymphoma (PTCL)
Disease Site: Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 20126
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (CTRL-ALT-D)
Disease Site: Non-Hodgkin's Lymphoma, Myeloid and Monocytic Leukemia, Leukemia, other, Hodgkin's Lymphoma, Lymphoid Leukemia, Acute Leukemia (ALL, AML), Myelodysplastic syndrome (MDS), NHL - Anaplastic large cell lymphoma (ALCL), NHL - Burkitt's lymphoma, NHL - Diffuse large cell lymphoma, NHL - lymphoblastic lymphoma, Other leukemia
View Trial DetailsCLINICAL TRIAL 20372
Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes
Disease Site: Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 20397
A Phase 2, Single-Arm, Open-Label Study of Itacitinib, for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy
Disease Site: Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 50376
Pilot Study of Using MRD as a Predictor of Response after Axicabtagene Ciloleucel in Patients with Indolent Lymphomas
Disease Site: Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 18783
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
Disease Site: Lymphoid Leukemia, Non-Hodgkin's Lymphoma, Leukemia, other, Hodgkin's Lymphoma, Myeloid and Monocytic Leukemia, Acute Leukemia (ALL, AML), Chronic Leukemia (CLL, CML), Other leukemia
View Trial Details